title: Fas-mediated apoptosis in human prostatic carcinoma cell lines.
abstract: Of six prostatic carcinoma cell lines examined (ALVA31, DU145, JCA1, LNCaP, ND1, and PC3) by flow cytometric analysis, all were found to be positive for Fas antigen. Furthermore, of the prostate tissue specimens studied (six cases), all revealed Fas expression in benign and malignant epithelial cells. The agonistic anti-Fas monoclonal antibody (IPO-4) induced apoptosis in only two of six cell lines investigated, PC3 and ALVA31. PCR analysis indicated that all cell lines expressed normal transmembrane and death domains of Fas antigen. Using Western blot analysis, we found abundant expression of p53 in the cytoplasm of two Fas-resistant cell lines, DU145 and ND1, and did not find p53 in two Fas-sensitive cell lines, PC3 and ALVA31. Western blot and PCR analysis did not show consistent differences between cell lines examined in the expression of Bcl-2, Bcl-X(L), Bcl-X(S), and Bak. In contrast, Bax protein was not detected in two Fas-resistant cell lines, DU145 and ND1. We also showed that three Fas-resistant cell lines, DU145, ND1, and JCA1, expressed CD40, whereas the two Fas-sensitive cell lines, PC3 and ALVA31, were CD40 negative. Fas-sensitive cell lines were transfected with the cDNA encoding CD40, and the CD40-positive transfectant became more resistant to growth inhibition mediated by treatment with TNF-alpha and anti-Fas monoclonal antibody. Treatment with cycloheximide converted the phenotype of resistant cell lines from Fas resistant to Fas sensitive. Moreover, anti-Fas treatment of both resistant and sensitive cell lines induced rapid tyrosine phosphorylation or dephosphorylation of multiple proteins. These results suggest that the apoptotic machinery involved in DNA fragmentation is already in place in Fas-resistant cell lines, and thus, Fas-mediated apoptosis could be a target for therapeutic intervention.
authors.affiliation: Department of Pathology, University of Iowa, Iowa City 52242, USA.
authors.forename: O W
authors.initials: OW
authors.lastname: Rokhlin
authors.forename: G A
authors.initials: GA
authors.lastname: Bishop
authors.forename: B S
authors.initials: BS
authors.lastname: Hostager
authors.forename: T J
authors.initials: TJ
authors.lastname: Waldschmidt
authors.forename: S P
authors.initials: SP
authors.lastname: Sidorenko
authors.forename: N
authors.initials: N
authors.lastname: Pavloff
authors.forename: M C
authors.initials: MC
authors.lastname: Kiefer
authors.forename: S R
authors.initials: SR
authors.lastname: Umansky
authors.forename: R A
authors.initials: RA
authors.lastname: Glover
authors.forename: M B
authors.initials: MB
authors.lastname: Cohen
mesh_terms: D000937:Antigen-Antibody Reactions; D017209:Apoptosis; D019013:CD40 Antigens / Q000235:genetics / Q000378:metabolism; D002455:Cell Division; D003513:Cycloheximide / Q000494:pharmacology; D053938:DNA Fragmentation; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D019000:Phosphotyrosine / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015398:Signal Transduction; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein; D019014:fas Receptor / Q000502:physiology*
chemical_list: C494826:BAX protein, human; C494811:BCL2L1 protein, human; D019013:CD40 Antigens; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein; D019014:fas Receptor; D019000:Phosphotyrosine; D003513:Cycloheximide; D017027:Protein Tyrosine Phosphatases